Rgma-flox Mouse

Rgma, or Repulsive guidance molecule A, is a glycosylphosphatidylinositol-linked glycoprotein. It was originally identified as a neuronal growth cone-collapsing factor and has multiple functions, including regulating axon guidance, neuronal differentiation, survival, and immune regulation. It exerts its functions mainly through binding to its receptor neogenin, thus playing a significant role in the development and pathology of the central nervous system (CNS) [1,3,4].

In disease-related research, knockdown of Rgma in mouse models has shown promising results. In mSOD1 mice (a model for amyotrophic lateral sclerosis, ALS), treatment with humanized anti-Rgma monoclonal antibody ameliorated clinical symptoms by reducing mutant SOD1 protein accumulation in motor neurons via inhibiting actin depolymerization [1]. In a mouse model of ischemia-reperfusion (I/R), knockdown of Rgma shifted neuronal energy metabolism towards oxidative phosphorylation and the pentose phosphate pathway, protecting mice from I/R injury [2]. In a neuromyelitis optica (NMO) rat model, treatment with Rgma-mAb suppressed neutrophil infiltration, decreased the expression of neutrophil chemoattractants, and ameliorated astrocytopathy and neuropathic pain [3]. In ApoE-/-mice, knockdown of Rgma inhibited the dedifferentiation of oxidized LDL-induced vascular smooth muscle cells (VSMCs), their proliferation and migration, and reduced neointima thickness [5]. In an experimental autoimmune encephalomyelitis (EAE) mouse model (related to multiple sclerosis), knockdown of Rgma strengthened the integrity of the blood-brain barrier (BBB) [6].

In conclusion, Rgma is a multifunctional molecule involved in various biological processes. Studies using gene-knockout or antibody-based loss-of-function models in different animal models have revealed its significant role in diseases such as ALS, I/R injury, NMO, atherosclerosis-related conditions, and multiple sclerosis. These findings suggest that targeting Rgma could potentially be a therapeutic strategy for these diseases.